Evotec AG has entered a strategic collaboration with Carna Biosciences. Carna will access Evotec’s INDiGO platform to accelerate the development of its program CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration. “We are excited to initiate IND-enabling studies for our next-generation non-covalent BTK inhibitor, CB-1763, in collabora...